期刊文献+

特异性免疫治疗疗效起始时间研究 被引量:6

原文传递
导出
摘要 目的:对变应原特异性免疫治疗(皮下注射)起效时间进行分析。方法:选择对尘螨过敏的变应性鼻炎患者64例,在不给予辅助治疗的情况下行特异性免疫治疗(皮下注射)。每周随访,以症状评分的有效下降作为特异性免疫治疗有效的标准,记录起效时间,并检测治疗前和治疗起效时的血清IL-4浓度。结果:64例患者治疗后开始起效的时间分别在9~17周之间,平均为12.6周。治疗后患者血清IL-4水平较治疗前有下降,但和治疗前比较差异无显著性(P>0.05)。结论:特异性免疫治疗起效时间平均为12.6周,即治疗后约3个月开始发挥作用。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2009年第19期1688-1689,共2页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献5

二级参考文献9

  • 1Zlotnik I,Chyrek-Borowska S,Siergiejko Z.Specific immunotherapy in patients with bronchial asthma hypersensitive to housedust mites. Pneumonol Alergol Pol, 1995,63:42-51.
  • 2Tazaki T, Minoguchi K, Yokoe T,et al.Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor beta2 chain expression in patients with allergic asthma.Cell Immunol,2004,228:20-26.
  • 3Bodtger U, Linneberg A. Remission of allergic rhinitis:An 8-year observational study. J Allergy Clin Immunol,2004,114:1384-1388.
  • 4Bousquet J,Van Cauwenberge P,Khaltaev N et al.Allergic rhinitis and its impact on asthma.J Allergy Clin Immunol,2001,108(5 Suppl):147.
  • 5Meltzer EO.Allergic rhinitis:managing the pediatric spe-ctrum.Allergy Asthma Proc,2006,27(1):2.
  • 6Bousquet J,Lockey R,Malling HJ.Allergen immunotherapy:Therapeutic vaccines for allergic diseases.World Health Organization Position Paper.Allergy,1998,53(Suppl 44):1.
  • 7Niggemann B,Jacobsen L,Dreborg S et al.Five-year follow-up on the PAT study:specific immunotherapy and long-term prevention of asthma in children.Allergy,2006,61(7):855.
  • 8顾瑞金,顾之燕.变应性鼻炎诊断和疗评定标准专题学术讨论会纪要[J].中华耳鼻咽喉科杂志,1991,26(3):131-133. 被引量:142
  • 9马未央,陈科达,张立煌.变应性鼻炎患者外周血4种细胞因子和黏附分子的检测[J].中华耳鼻咽喉科杂志,2003,38(6):406-406. 被引量:9

共引文献1718

同被引文献85

  • 1顾之燕,董震.变应性鼻炎的诊治原则和推荐方案(2004年,兰州)[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):166-167. 被引量:1713
  • 2王忠喜.变应性鼻炎患者脱敏治疗前后尘螨特异性IgE和白细胞介素水平的变化[J].临床耳鼻咽喉科杂志,2005,19(17):772-773. 被引量:6
  • 3赵建东,王世振,马凤梅.Th1和Th2细胞及相关细胞因子在变应性鼻炎发病中的变化[J].临床耳鼻咽喉科杂志,2005,19(17):794-796. 被引量:31
  • 4Dehlink E, Eiwegger T, Gerstmayr M,et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children[J]. Clin Exp Allergy, 2006,36 ( 1 ) : 32-39.
  • 5Cosmi L, Santarlasci V, Angeli R. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down regulates allergen-specific immunoglobulin E and increases both interfer on-gamma and interleukin 10 production[J]. Clin Exp Allergy,2006,36(3) :261-272.
  • 6Rolinck- Werninghaus C, Kopp M, Liebke C. Lack of detect able alterations in immune responses during sublingual immu notherapy in children with seasonal allergic rhinoconjunetivitis to grass pollen[J].Int Arch Allergy Immunol, 2005, 136 (2) : 134-141.
  • 7Ciprandi G,de Amici M,Murdaca G. Serum IL-4 as a marker of immunological response to sublingual immunotherapy[J]. J Biol Regul Homeost Agents,2008,22(2) : 117-123.
  • 8Savolainen J, Nieminen K, Laaksonen K,et al. Allergen-induced in vitro expression of IL- 18,SLAM and GATA3 mRNA in PBMC during sublingual immunotherapy[J]. Auergy,2007, 62(8) :949- 953.
  • 9Tazaki T, Minoguchi K, Yokoe T. Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor beta2 chain expression in patients with allergic asthma[J]. Cell Immunol, 2004,228 ( 1 ) : 20-26.
  • 10Zhang L, Han D, Huang D, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in china I-J]. Int Arch A1- lergyImmunol, 2009, 149 (1).. 47-57.

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部